Mode
Text Size
Log in / Sign up
Phase 3 Completed N=445 Randomized Quadruple-blind Treatment

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Source: ClinicalTrials.gov NCT04178967 ↗
Enrolled (actual)
445
Serious AEs
2.0%
Results posted
Sep 2022
Primary outcomePrimary: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 — 10.8; 33.2 percentage of participants — p=0.000004
◆ Published Evidence
Emerging
11citations · ~6 / year
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.
Dermatology and therapy · 2024 · Open access · Likely link

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.

Linked Publications (5)

  • Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.
    Dermatology and therapy · 2024 · 11 citations · Open access · Likely link
  • Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).
    Advances in therapy · 2025 · 9 citations · Open access · Likely link
  • Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis.
    Dermatology and therapy · 2025 · 8 citations · Open access · Likely link
  • Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026 · 0 citations · Open access · Likely link
  • Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.
    Clinical and experimental dermatology · 2026 · 0 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16
10.8; 33.2 0.000004 sig
PRIMARY
Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16
18.1; 52.1 <0.000001 sig
SECONDARY
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 2
0; 0.7 0.308463
SECONDARY
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 4
1.4; 9.0 0.001607 sig
SECONDARY
Percentage of Participants With an IGA Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16
10.8; 33.2 0.000004 sig
SECONDARY
Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) From Baseline to Week 16
9.5; 30.7 0.000008 sig
SECONDARY
Percentage Change in Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
-9.02; -36.56 <0.000001 sig
SECONDARY
Percentage of Participants With a Pruritus NRS Score of ≥4-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16
11.5; 39.8 <0.000001 sig
SECONDARY
Percentage of Participants With a Pruritus NRS Score of ≥5-points at Baseline Who Achieve a ≥4-point Reduction in Pruritus NRS Score From Baseline to Week 16
11.8; 41.6 <0.000001 sig
SECONDARY
Percentage Change in EASI Score From Baseline to Week 16
-27.96; -61.53 <0.000001 sig
SECONDARY
Change From Baseline in Percent Body Surface Area (BSA) at Week 16
-14.0; -30.2 <0.000001 sig
SECONDARY
Percentage of Participants Achieving EASI-90 From Baseline to Week 4
1.5; 6.3 0.022921 sig
SECONDARY
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
-2.4; -7.3 <0.000001 sig
SECONDARY
Percentage of Participants Achieving ≥4-point Improvement in DLQI From Baseline to Week 16
32.8; 65.4 0.000001 sig
SECONDARY
Percentage of Participants With a DLQI Total Score of ≥4-point at Baseline Achieving ≥4-point Improvement in DLQI From Baseline to Week 16
33.6; 66.3 0.000001 sig
SECONDARY
Percentage Change in Sleep-loss Score From Baseline to Week 16
-11.29; -48.37 <0.000001 sig
SECONDARY
Change From Baseline in Sleep-loss Score at Week 16
-0.35; -1.05 <0.000001 sig
SECONDARY
Percentage of Participants With a Sleep-loss Score ≥2 Points at Baseline Who Achieve a ≥2 Points Reduction From Baseline to Week 16
8.2; 28.0 0.000571 sig
SECONDARY
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1
0.0; 0.4 0.469221
SECONDARY
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2
0.7; 3.6 0.113194
SECONDARY
Percentage of Participants With a Pruritus NRS Score of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4
3.0; 16.8 0.000230 sig
SECONDARY
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 1
0.0; 0.4 0.468160
SECONDARY
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 2
0.8; 3.9 0.115770
SECONDARY
Percentage of Participants With a Pruritus NRS Score of ≥5 Points at Baseline Who Achieve a ≥4-point Reduction From Baseline to Week 4
3.3; 18.1 0.000252 sig
SECONDARY
Percentage Change in SCORing Atopic Dermatitis (SCORAD) From Baseline to Week 16
-13.81; -44.57 <0.000001 sig
SECONDARY
Pharmacokinetics (PK): Trough Serum Concentrations of Lebrikizumab in Maintenance Period (C-trough)
46.7; 90.5
SECONDARY
Percentage of Participants From Those Re-randomized Having Achieved EASI-75 at Week 16 Who Continue to Exhibit EASI-75 at Week 52 (EASI-75 Calculated Relative to Baseline EASI Score)
72.0; 84.7; 77.4 0.238245
SECONDARY
Percentage of Participants From Those Re-randomized Having Achieved IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 16 Who Continue to Exhibit an IGA 0 or 1 and a ≥2-point Improvement From Baseline at Week 52
49.8; 80.6; 64.6 0.033876 sig
SECONDARY
Percentage of Participants From Those With a Pruritus NRS of ≥4-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52
67.6; 88.1; 90.3 0.159281
SECONDARY
Percentage of Participants From Those With a Pruritus NRS of ≥5-points at Baseline Re-randomized Having Achieved ≥4-point Reduction From Baseline at Week 16 Who Continue to Exhibit ≥4-point Reduction From Baseline at Week 52
67.6; 87.4; 94.4 0.179704
SECONDARY
Percentage Change in SCORAD (From Those Re-randomized Having Achieved EASI-75 at Week 16) From Baseline at Week 52
-67.60; -73.89; -73.85 0.176748
SECONDARY
Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) at Week 16 - Health State Index
0.0; 0.1; 0.0; 0.1 0.000001 sig
SECONDARY
Change From Baseline in EQ-5D-5L at Week 16 - Visual Analog Scale (VAS)
5.2; 9.7 0.005304 sig
SECONDARY
Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16
-3.5; -9.5 <0.000001 sig
SECONDARY
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety at Week 16-Adolescents
0.12; -2.79 0.241275
SECONDARY
Change From Baseline in PROMIS Anxiety at Week 16 - Adults
-0.45; -3.18 0.000116 sig
SECONDARY
Change From Baseline in PROMIS Depression at Week 16- Adolescents
-0.57; -1.67 0.645132
SECONDARY
Change From Baseline in PROMIS Depression at Week 16- Adults
0.16; -2.59 0.000031 sig
SECONDARY
Change From Baseline in Asthma Control Questionnaire (ACQ-5) Score at Week 16 in Participants Who Have Self-reported Comorbid Asthma
0.19; 0.19 0.974417
SECONDARY
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16
-3.4; -7.6 0.084769

Eligibility Criteria

Inclusion Criteria

  • Male or female adults and adolescents (≥12 years and ≥40 kg)
  • Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit
  • Eczema Area and Severity Index (EASI) score ≥16 at the baseline visit
  • Investigator Global Assessment (IGA) score ≥3 (scale of 0 to 4) at the baseline visit
  • ≥10% body surface area (BSA) of atopic dermatitis involvement at the baseline visit
  • History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable

Exclusion Criteria

  • Prior treatment with dupilumab or tralokinumab
  • Treatment with topical corticosteroids, calcineurin inhibitors or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to the baseline visit
  • Treatment with any of the following agents within 4 weeks prior to the baseline visit:
  • Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)
  • Phototherapy and photochemotherapy (PUVA) for AD
  • Treatment with the following prior to the baseline visit:
  • An investigational drug within 8 weeks or within 5 half-lives (if known) of baseline, whichever is longer
  • Cell-depleting biologics, including to rituximab, within 6 months of baseline
  • Other biologics within 5 half-lives (if known) or 16 weeks of baseline, whichever is longer
  • Treatment with a live (attenuated) vaccine within 12 weeks of the baseline visit or planned during the study
  • Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma
  • Evidence of active acute or chronic hepatitis
  • History of human immunodeficiency virus (HIV) infection or positive HIV serology
  • History of malignancy, including mycosis fungoides, within 5 years before the screening visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04178967) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search